Segment Information (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Segment Information, Including Significant Segment Expenses

The following tables set forth our segment information, including significant segment expenses that are (or are easily computable from) information regularly provided to our CODM, for the three months ended March 31, 2026 and 2025 (in thousands):


		Three Months Ended March 31, 2026												Three Months Ended March 31, 2025
		MRD				Immune Medicine				Total				MRD				Immune Medicine(1)				Total
Revenue		$	67,093			$	3,781			$	70,874			$	43,721			$	8,722			$	52,443
Less:
Cost of revenue			17,244			*					17,244				15,885			*					15,885
Research and development			9,226				13,934				23,160				9,159				14,488				23,647
Sales and marketing			24,742			*					24,742				21,413			*					21,413
General and administrative			12,519			*					12,519				9,502			*					9,502
Other segment items(2)			—				5,776				5,776				—				5,153				5,153
Add back:
Items to reconcile net income or net loss to Adjusted EBITDA(3)			8,776				5,569				14,345				8,127				5,813				13,940
Adjusted EBITDA(3)			12,138				(10,360	)			1,778				(4,111	)			(5,106	)			(9,217	)
Items to reconcile to consolidated net loss:
Share-based compensation expense(4)											(9,969	)											(9,654	)
Restructuring expense(5)											(643	)											—
Impairment of long-lived assets(5)											(347	)											—
Depreciation and amortization expense											(3,386	)											(4,286	)
Other unallocated items(1)											(7,448	)											(6,673	)
Net loss										$	(20,015	)										$	(29,830	)
*Non-significant segment expenses for Immune Medicine.

(1) Costs related to Digital Biotechnologies, Inc. are no longer included as Immune Medicine costs and have been reclassified to the “other unallocated items” total.

(2) For the Immune Medicine segment, includes all Immune Medicine operating expenses, other than research and development expenses.

(3) Adjusted EBITDA is a non-GAAP financial measure. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.

(4) Represents share-based compensation expense related to various awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.

(5) Represents expenses recognized in conjunction with a restructuring that primarily impacted research and development activities.